Agomab Therapeutics NV (AGMB)
Market Closed
27 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
12. 51
0
0%
$
616.09M Market Cap
- P/E Ratio
- Div Yield
33,102 Volume
- Eps
$ 12.51
Previous Close Investors:
Want to track AGMB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
AgomAb Therapeutics: High Risk, High Reward Stock
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drugs targeting large addressable markets. AGMB-129 (Crohn's disease) and AGMB-447 (IPF) have Fast Track and Orphan Drug designations, indicating significant unmet need and regulatory advantages. Strong backing from major pharma players and a high institutional ownership position, AGOM is a potential acquisition target upon successful trial outcomes.
Seekingalpha | 1 month ago
